American Journal of Psychiatry· Yiwei LinHaotian LiMilap C. NahataChen ZhangOlivia L. RameyLigang Liu1Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital of Capital Medical University, Beijing. 2School of Biological Sciences, University of Nebraska–Lincoln, Lincoln. 3Institute of Therapeutic Innovations and Outcomes, Colleges of Pharmacy and Medicine, Ohio State University, Columbus. 4Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha. 5Division of Pharmacotherapy and Translational Sciences, College of Pharmacy, University of Texas at Austin, Austin. 6Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA.·· 2026-07-08精选AI 评分62
美国共病物质使用障碍与精神障碍成人的治疗模式与就医障碍
Treatment Patterns and Barriers to Care Among U.S. Adults With Co-Occurring Substance Use Disorder and Mental Illness
AI 导读
一项基于2021至2023年美国全国药物使用与健康调查的横断面研究显示，在同时患有物质使用障碍与任何精神障碍的成人中，过去一年同时接受两种治疗的比例从2021年的7.5%升至2022年的16.9%和2023年的18.2%；在共病严重精神障碍者中，该比例从12.3%升至25.0%和25.6%。
推荐理由
基于全美调查数据，呈现共病成瘾与精神障碍人群接受双重治疗的比例变化及未治疗者面临的障碍。
来源：American Journal of Psychiatry · psychiatryonline.org